Evidence map›Paper›PMID 42422436›Full record

SynthesisFrontiers in endocrinology2026

The metabolic syndrome-cancer axis: global research trends and clinical landscapes.

Dianzhe Tian, Xinshi Li, Jiajie Lin, Zuyi Yang, Xinyu Zhao, Zixuan Hu, Haitao Zhao, Shunda Du, Shengzhi Liu, Lei Zhang and 2 more

Abstract readSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Dianzhe Tian *Department of Liver Surgery, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Xinshi Li *Department of Pharmacology, College of Pharmaceutical Sciences of Capital Medical University, Beijing, China.
Jiajie Lin *Eight-year Medical Doctor Program, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Zuyi Yang *Eight-year Medical Doctor Program, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Xinyu ZhaoKey Laboratory of Ocular Fundus Disease, Chinese Academy of Medical Sciences, Beijing, China.
Zixuan HuDepartment of Liver Surgery, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Haitao ZhaoDepartment of Liver Surgery, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Shunda DuDepartment of Liver Surgery, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Shengzhi LiuDepartment of Pharmacology, College of Pharmaceutical Sciences of Capital Medical University, Beijing, China.
Lei ZhangDepartment of Liver Surgery, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Yiyao XuDepartment of Liver Surgery, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Xin LuDepartment of Liver Surgery, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The link between metabolic syndrome (MetS) and cancer has been widely studied, but overall research patterns, shared mechanisms, and applications remain unclear. A bibliometric and bioinformatics analysis is needed to identify trends and clarify the molecular pathways connecting MetS to cancer. Methods: A bibliometric analysis using Web of Science and PubMed assessed publication trends, collaboration, key authors/journals, and research topics from 2000 to 2024. Visualization and analysis used VOSviewer, CiteSpace, and Bibliometrix. Also included bioinformatics for protein interaction networks, hub genes, and enrichment analysis via R pipelines. Results: Research output grew mainly driven by China and the US, with Europe showing high collaborative centrality. Thematic analysis shifted from isolated metabolic issues to integrated MetS phenotypes, cancer prognosis, and interventions. Bioinformatics found hub genes and pathways linking metabolic dysregulation with tumor development, especially involving inflammation, insulin signaling, and metabolic reprogramming. Conclusions: This analysis supports a bidirectional MetS-cancer link and shifts focus from tumor-centric to a holistic view of the tumor-host metabolic system. Targeting metabolic dysfunction may improve cancer prognosis, treatment tolerance, and outcomes.

Indexed as

Biomedical ResearchMetabolic SyndromeNeoplasmsBibliometricsComputational BiologyHumansbibliometric analysisbiomarkercancermetabolic syndromemetabolism

Identifiers

PMID42422436
PMCPMC13343530

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.